Semaglutide

GLP-1 receptor agonist by Novo Nordisk (“SEM-a-GLOO-tide”) FDA approved 2017

By the GLP Index editorial team Updated How we source

Semaglutide is a GLP-1 receptor agonist sold as Ozempic, Wegovy and Rybelsus. It now comes in five products across two routes, on different dose scales.

What is semaglutide?

Semaglutide is the active ingredient behind Ozempic, Wegovy and Rybelsus, not a brand itself. It is a GLP-1 receptor agonist made by Novo Nordisk, first approved in 2017, and it acts on the receptor for a hormone your gut already releases when you eat.

Because it is the molecule rather than the label, “semaglutide” is what appears in trials and on a prescription, while the pharmacy hands you a specific product. Which product depends on what is being treated, and increasingly on whether you want an injection or a tablet. That last choice is no longer a simple one: there are now five semaglutide products across two routes, and their dose numbers are not comparable.

Semaglutide brand names: Ozempic, Wegovy & Rybelsus

Novo Nordisk sells semaglutide under three brand names, but those three names cover five distinct products, because Ozempic and Wegovy each come in two routes with different ladders and different indications.

ProductRouteApproved forMaintenance dose
Ozempic injectionWeeklyType 2 diabetes, plus cardiovascular and kidney risk0.5, 1 or 2 mg
Ozempic tabletsDailyType 2 diabetesup to 9 mg
Wegovy injectionWeeklyWeight management, cardiovascular risk, MASH, ages 12+1.7 or 2.4 mg, optional 7.2 mg
Wegovy tabletsDailyWeight management and cardiovascular risk, adults only25 mg
RybelsusDailyType 2 diabetes, plus cardiovascular risk7 or 14 mg

Three things this table is trying to prevent. Milligrams do not transfer between rows: the label states Rybelsus and Ozempic tablets are not substitutable on a milligram-to-milligram basis, and the three oral products run on three different scales. “Wegovy” is not one thing: the pediatric and MASH indications belong to the injection only. And the missed-dose rules for the Wegovy injection and the Wegovy tablets point in opposite directions, on the same label.

There is no FDA-approved generic semaglutide. Anything sold as “generic Ozempic” or “generic semaglutide” is compounded or counterfeit. See compounded semaglutide below.

Injection vs pill

The tablets are needle-free, but oral semaglutide is absorbed poorly and variably, so all three oral products must be taken fasting, with no more than 4 ounces of plain water, swallowed whole, followed by at least 30 minutes before anything else. That routine is part of the dose rather than a convenience note.

It also explains something counterintuitive: oral semaglutide has roughly the same week-long half-life as the injection but is taken daily, because absorption rather than duration is the limiting factor.

How does semaglutide work?

Semaglutide mimics GLP-1, a hormone your gut releases after you eat. That does three things:

  1. Quiets appetite signals in the brain, so you feel full sooner and think about food less.
  2. Slows stomach emptying, so meals keep you satisfied longer.
  3. Sharpens insulin response, steadying blood sugar after meals.

Semaglutide targets a single receptor (GLP-1), which is what distinguishes it from dual-agonist tirzepatide, the leading explanation for tirzepatide’s larger trial numbers. Both belong to the broader GLP-1 drug class.

Receptors it activates

Single agonist · GLP-1

  • GLP-1

    Curbs appetite and triggers insulin after meals

  • GIP

    Not activated

  • glucagon

    Not activated

How much weight can you lose on semaglutide?

How much depends on which product and which dose, so the numbers below name both.

At the 2.4 mg weight-management injection, adults with obesity and without diabetes lost about 15 percent of body weight over 68 weeks, against 2.4 percent on placebo. People who also have type 2 diabetes lose meaningfully less on the same drug and dose, closer to 10 percent.

The newer products extend the range in both directions. The higher 7.2 mg injection reached 18.8 percent over 72 weeks, against 15.5 percent at 2.4 mg in the same trial. The 25 mg tablet produced 13.6 percent over 64 weeks against placebo, in a trial with no injection arm, so the tablet and the injection have never been compared directly.

The diabetes-dose products are a different story again: Ozempic’s own trials, at the doses its pen delivers, produced roughly 8 to 10 lb rather than a percentage headline.

~15%

~35 lb · 68 weeks

STEP 1, 2.4 mg injection 3

18.8%

72 weeks

Wegovy Study 8, 7.2 mg injection 1

13.6%

64 weeks

Wegovy Study 7, 25 mg tablet 1

Here is how the pivotal trials break down by population, product and dose:

Semaglutide weight results by trial, product and dose. Trial names link to ClinicalTrials.gov.
Trial Dose Duration Avg. weight loss Studied in
STEP 1 2.4 mg injection 68 weeks ~15% (~35 lb) Adults with obesity, no diabetes
STEP 2 2.4 mg injection 68 weeks 9.6% (~22 lb) Adults with obesity and type 2 diabetes
Wegovy Study 8 7.2 mg injection 72 weeks 18.8% Adults with obesity, no diabetes
Wegovy Study 7 25 mg tablet 64 weeks 13.6% Adults with obesity, no diabetes

Two caveats apply to every figure. No trial number is the drug on its own: every arm also received structured lifestyle support, and the drug effect was measured on top of it. And these are group averages, with wide variation between individuals in every arm.

What are the side effects of semaglutide?

Mostly digestive, mostly early, mostly temporary. They cluster around dose increases and ease as your body adjusts. The rates below span the dose range, from the diabetes-dose trials at the low end to the 2.4 mg weight-management trials at the high end, each shown against the placebo rate in its own trials. That span is not a ranking: different doses, different populations, different trials, and no label permits comparing them directly.

Common · usually temporary

  • Nausea 16–44% vs 6–16%
  • Diarrhea 9–30% vs 2–16%
  • Vomiting 5–24% vs 2–6%
  • Constipation 3–24% vs 2–11%
  • Abdominal pain 6–20% vs 5–10%
  • Headache 14% vs 10%
  • Fatigue 11% vs 5%

Serious · call your provider

  • Thyroid C-cell tumors (boxed warning, from rodent studies)
  • Acute pancreatitis
  • Acute gallbladder disease
  • Diabetic retinopathy complications
  • Low blood sugar
  • Acute kidney injury from dehydration
  • Severe digestive reactions
  • Serious allergic reactions
  • Increased resting heart rate
  • Pulmonary aspiration during general anesthesia or deep sedation

One warning is specific to semaglutide rather than the class. In the two-year cardiovascular trial, diabetic retinopathy complications occurred in 3.0 percent on semaglutide against 1.8 percent on placebo, concentrated in people who already had retinopathy. The tirzepatide labels say something different, that the drug has not been studied in the relevant eye disease, which is an absence of data rather than a comparable finding.

The suicidality warning was removed in February 2026 from the three labels that carried it, which for this molecule means Wegovy. Ozempic and Rybelsus never carried it.

Practical management, which rests on clinical experience rather than trials of the advice itself: smaller meals, less fatty food and alcohol around dosing, and enough fluid. Persistent severe abdominal pain is not a symptom to wait out.

Semaglutide side effects: the complete guide Every reported effect, how long each lasts, and how to manage them

Who should not take semaglutide?

Semaglutide is a fit for most adults who qualify for it, but two conditions make it a hard no, across every product, and several more are worth flagging to your prescriber before you start.

Do not take semaglutide if…

  • You or a family member has had medullary thyroid carcinoma (MTC)
  • You have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
  • You've had a serious hypersensitivity reaction to semaglutide or any ingredient in these products

Talk to your provider first if…

  • You've had pancreatitis or gallbladder disease
  • You have diabetic retinopathy or other existing eye disease
  • You have kidney disease or a history of dehydration
  • You take insulin or a sulfonylurea (higher risk of low blood sugar)
  • You already take another GLP-1 medicine, which the labels advise against
  • You have a surgery or procedure scheduled that needs anesthesia or sedation
  • You're pregnant, planning to be, or breastfeeding

The boxed warning drives the absolute contraindications: because semaglutide caused thyroid C-cell tumors in rodents, anyone with a personal or family history of medullary thyroid cancer or MEN 2 should not take it, whichever product it is dispensed as. Everything in the second column is not a stop sign; it is a reason to make sure your provider has the full picture first.

Semaglutide dosage: how the schedule works

Every product starts low and steps up, because the ramp is what limits the digestive side effects. But there is no single semaglutide ladder. Each product has its own, and the ceilings are not comparable:

ProductLadderMaximum
Ozempic injection0.25 → 0.5 → 1 → 2 mg weekly2 mg
Wegovy injection0.25 → 0.5 → 1 → 1.7 → 2.4 mg weekly2.4 mg, optional 7.2 mg
Rybelsus3 → 7 → 14 mg daily14 mg
Ozempic tablets1.5 → 4 → 9 mg daily9 mg
Wegovy tablets1.5 → 4 → 9 → 25 mg daily25 mg
The Wegovy injection ladder, per the FDA label, shown as the reference schedule. Every other semaglutide product runs a different one. Your prescriber sets your pace.
Dose When Notes
0.25 mg Weeks 1–4 Starting dosage on the injection. Not a maintenance dose.
0.5 mg Weeks 5–8 Second step
1 mg Weeks 9–12 Third step, and Ozempic's usual maintenance dose
1.7 mg Weeks 13–16 Fourth step, and a maintenance option the Wegovy label names
2.4 mg Week 17 onward Wegovy's usual maintenance dose. Ozempic tops out at 2 mg.

Missed doses split by product, not by molecule. The Ozempic label allows 5 days. The Wegovy injection uses a different rule entirely, keyed to how far the next dose is: take it if the next one is more than 2 days away, skip it if less. All three daily tablets say to skip the missed dose and take the next one the following day. Wegovy injection and Wegovy tablets sit on the same label with opposite instructions, which is the easiest mistake to make here.

How much does semaglutide cost?

Price depends on which product you are prescribed and what your plan does with it. List prices run roughly $935 to $1,349 a month across the range, and most people do not pay list.

List price, across the products
~$935–$1,349/mo approximate, before savings or insurance
Wegovy tablets, self-pay
from $149/mo 1.5 mg or 4 mg; the 4 mg moves to $199 after 31 August 2026
Wegovy injection pen, self-pay
$199/mo introductory first 2 months for new patients through 31 December 2026, then $349
Announced 2027 list price
$675/mo Novo Nordisk's announced uniform price for its semaglutide products from Jan 1, 2027

Savings cards can lower costs for people with commercial insurance, but they exclude anyone on Medicare, Medicaid, VA or TRICARE coverage, and several of the self-pay prices above are dated introductory offers with a scheduled step-up.

Because each product is priced and covered differently, the full breakdowns live on the brand pages: Ozempic cost, Wegovy cost, and Rybelsus cost.

What semaglutide costs, product by product List prices, self-pay ladders, savings-card fine print and coverage

The honest version is that this route has largely closed, though not quite as cleanly as either side claims.

Mass compounding rested on semaglutide being on the FDA’s shortage list, and that shortage was declared resolved in February 2025, which removed the basis for it. FDA’s actual standard has three separate parts rather than one: whether a compounded product is essentially a copy of an approved drug, whether a prescriber has determined a significant difference for an individual patient (a route that exists under 503A and has no equivalent under 503B), and the shortage list as an independent supply gate. A proposal to bar GLP-1s from the 503B bulk-substances list was still pending rather than final as of August 2026.

We cover this landscape informationally, meaning where it stands legally, how to tell a licensed pharmacy from a grey-market seller, and what the risks are. We do not recommend any compounded seller.

One practical hazard worth naming: compounded semaglutide is sometimes dosed in units rather than milligrams, which has produced measurement and concentration errors. If you are handed a syringe rather than a pen, confirm the exact unit-to-milligram conversion with the prescriber or pharmacy before drawing a dose.

Compounded semaglutide, in full Where the law actually stands, and how to spot a grey-market seller

Semaglutide vs other GLP-1 drugs

The short version: semaglutide is the most established GLP-1 medication and the only one with a pill, tirzepatide is stronger on trial numbers, and liraglutide is the older daily option.

Attribute Semaglutide Tirzepatide Liraglutide
Active ingredient semaglutide tirzepatide liraglutide
Sold as Ozempic · Wegovy · Rybelsus Mounjaro · Zepbound Victoza · Saxenda
Receptors targeted Single: GLP-1 Dual: GIP · GLP-1 Single: GLP-1
How it’s taken Weekly injection · Daily pill Weekly injection Daily injection
FDA-approved for Type 2 diabetes · Weight management Type 2 diabetes · Weight management & sleep apnea Type 2 diabetes · Weight loss
Avg. weight loss in trials ~15% ~21% ~7%
List price (before insurance) ~$935–$1,349/mo ~$1,060–$1,070/mo
Maker Novo Nordisk Eli Lilly Novo Nordisk

Semaglutide vs Tirzepatide

Tirzepatide produced more weight loss in the one direct trial, but semaglutide carries cardiovascular outcome indications that no tirzepatide product has.

Semaglutide vs Liraglutide

Both are Novo Nordisk GLP-1 drugs, but semaglutide is weekly and stronger; liraglutide is a daily injection from an earlier generation.

How to get semaglutide

Semaglutide is prescription-only, dispensed as Ozempic, Wegovy, or Rybelsus. Three legitimate paths:

1

Through your doctor

Any prescriber can write semaglutide. Bring your insurance details, since coverage often requires prior authorization, and your doctor's office handles that paperwork.

2

Through telehealth

Licensed online clinics evaluate you remotely and, if appropriate, prescribe semaglutide or a semaglutide-based program, usually within a few days.

3

Pharmacy + savings

Prescriptions fill at regular pharmacies or the maker's direct program. Check the manufacturer savings card before paying list price.

Telehealth options we've reviewed

All provider reviews

No legitimate semaglutide without a prescription. Sellers offering it with no medical review are operating outside the law, and counterfeit pens are common. Stick to licensed providers and pharmacies. Important safety information

We're independent: we don't sell medication. Some links may earn us a commission at no cost to you; it never affects what we recommend. Prices change often, so always confirm with the provider.

Semaglutide myths and misconceptions

As the most talked-about molecule in the class, sold under three names and five products, semaglutide attracts a lot of noise. Here is what is actually true behind the five claims we hear most.

  • Myth There are three semaglutide products.

    There are five. Ozempic and Wegovy each come as an injection and as a tablet, plus Rybelsus. They run on different ladders and do not share every indication.

  • Myth There's a generic semaglutide in the US.

    None is FDA-approved. Semaglutide is under patent into the 2030s, so anything sold as generic semaglutide is compounded or counterfeit.

  • Myth Compounded semaglutide is the same as the brand.

    It isn't FDA-verified for dose, purity, or quality. Compounded copies sit in a legal grey zone since the shortage ended.

  • Myth Semaglutide and tirzepatide are equally strong.

    Tirzepatide produced more weight loss in the one direct trial. Semaglutide's counterweight is real though, since it carries cardiovascular outcome indications that no tirzepatide product has.

  • Myth A milligram is a milligram across semaglutide products.

    It is not, and the label says so outright. Rybelsus and Ozempic tablets are not substitutable milligram for milligram, and the oral and injectable scales are unrelated. Always name the product before the number.

FAQ

Common questions about Semaglutide

Is semaglutide the same as Ozempic?

Semaglutide is the active ingredient in Ozempic, and also in Wegovy and Rybelsus. Ozempic is a brand name for injectable semaglutide approved for type 2 diabetes; the drug inside is the same molecule sold under other names for other uses.

Ozempic overview
What's the difference between Ozempic, Wegovy, and Rybelsus?

All are semaglutide, but there are now five products rather than three. Ozempic is a weekly injection for type 2 diabetes and also comes as a tablet. Wegovy is the weight-management product, as a weekly injection and as a tablet. Rybelsus is a daily tablet for type 2 diabetes. Same molecule, different ladders, different approvals, and not interchangeable.

Is there a semaglutide pill?

There are three of them, which is the part most coverage misses. Rybelsus and Ozempic tablets are both for type 2 diabetes, on the same label but different dose scales, and the label says they are not substitutable milligram for milligram. Wegovy tablets go to 25 mg and carry the weight-management indication. All three are taken fasting with a small sip of water and a 30-minute wait.

Rybelsus overview
How much weight can you lose on semaglutide?

At the 2.4 mg weight-management dose, adults with obesity and without diabetes lost about 15 percent of body weight over 68 weeks against 2.4 percent on placebo. The higher 7.2 mg injection reached 18.8 percent over 72 weeks, and the 25 mg tablet 13.6 percent over 64 weeks. People with type 2 diabetes lose less on the same dose, closer to 10 percent.

Is there a generic version of semaglutide?

No. There is no FDA-approved generic semaglutide. Anything sold as "generic Ozempic" or "generic semaglutide" is either a compounded preparation or counterfeit.

Is compounded semaglutide legal?

The route has largely closed. Mass compounding rested on semaglutide being on the FDA shortage list, and that shortage was declared resolved in February 2025. FDA's standard has three separate parts, and a proposal to bar GLP-1s from the 503B bulk-substances list was still pending rather than final as of August 2026.

Compounded semaglutide
Is semaglutide the same as tirzepatide?

No. Semaglutide acts on one gut-hormone receptor; tirzepatide acts on two. In the one direct obesity trial, tirzepatide produced more weight loss, 20.2 percent against 13.7 percent. Semaglutide's counterweight is that it carries cardiovascular outcome indications and tirzepatide does not, and it is the only one of the two available as a tablet.

Tirzepatide vs semaglutide
Is semaglutide insulin?

No. Semaglutide is a GLP-1 receptor agonist, not insulin. It helps your body release its own insulin when blood sugar is high, but it is a completely different type of medication.

What is semaglutide microdosing?

"Microdosing" means taking smaller-than-labeled doses of semaglutide, almost always compounded, hoping for benefits with fewer side effects. It isn't an FDA-approved approach, the evidence behind it is thin, and because it relies on compounded product it carries the same quality and legality questions as any compounded semaglutide.

Sources

Every claim on this page traces to primary literature or FDA labeling. Browse the full evidence library.

  1. Wegovy prescribing information (FDA label) (Novo Nordisk / FDA)
  2. Rybelsus and Ozempic tablets prescribing information (FDA label) (Novo Nordisk / FDA)
  3. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) (New England Journal of Medicine, 2021)
  4. Semaglutide in Adults with Overweight/Obesity and Type 2 Diabetes (STEP 2) (The Lancet, 2021)
  5. Semaglutide injection (MedlinePlus drug information) (U.S. National Library of Medicine)
  6. Semaglutide (subcutaneous route), description and side effects (Mayo Clinic)
  7. FDA's concerns with unapproved GLP-1 drugs used for weight loss (U.S. Food & Drug Administration)
This page is for informational purposes only and isn't medical advice. Talk to a licensed healthcare provider about your situation before starting, stopping, or changing any medication. See our medical disclaimer and editorial policy.

Written by the GLP Index editorial team · Updated August 6, 2026 · How we source